Status:

COMPLETED

Dexmedetomidine and Adenosine: Therapeutic Use for SVT

Lead Sponsor:

University of Pittsburgh

Conditions:

Supraventricular Tachycardia

Eligibility:

All Genders

5-30 years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of Supraventricular Tachycardia (SVT).

Detailed Description

In 2006 the investigator found that dexmedetomidine, an alpha-2 adrenergic agonist with primarily sedative properties, possesses additional anti-arrhythmic properties. So far the investigator has foun...

Eligibility Criteria

Inclusion

  • Patients between the age of 5 - 30 years old, who are scheduled for cardiac electrophysiology study for evaluation of reentrant SVT

Exclusion

  • Severe Heart Failure
  • Presence of of any other antiarrhythmic medication within 24 hours of enrollment
  • Third degree heart block
  • Sick Sinus Syndrome

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT01495481

Start Date

January 1 2012

End Date

July 1 2014

Last Update

March 28 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Childrens Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States, 15224

Dexmedetomidine and Adenosine: Therapeutic Use for SVT | DecenTrialz